Preoperative Chemoradiotherapy Fails to Improve Survival in Gastric Cancer
• A phase III trial (TOPGEAR) found that adding preoperative chemoradiotherapy to perioperative chemotherapy did not significantly improve overall survival in patients with resectable gastric cancer.
• Median overall survival was similar in both groups: 46.4 months with preoperative chemoradiotherapy versus 49.4 months with perioperative chemotherapy alone.
• Preoperative chemoradiotherapy did improve pathological outcomes, doubling the pathological complete response rate and increasing tumor downstaging compared to perioperative chemotherapy alone.
• Real-world data shows perioperative chemotherapy (PC) is associated with improved overall survival (OS) in patients with gastric and GEJ cancer.
© Copyright 2025. All Rights Reserved by MedPath